High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Chromatography B: Biomedical Sciences and Applications

• Publication date

  2000-01-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0378-4347(99)00489-2PMID 10778930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression

  1998cited by this paper
• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts

  1997cited by this paper
• Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

  1997cited by this paper
• High-performance liquid chromatographic determination of fluconazole in plasma.

  1996cited by this paper
• Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography.

  1996cited by this paper
• High-performance liquid chromatographic analysis for the determination of miconazole in human plasma using solid-phase extraction.

  1996cited by this paper
• In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

  1996cited by this paper
• Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent

  1995cited by this paper
• Problems in management of opportunistic fungal diseases.

  1989cited by this paper

• Development and Validation of UV Spectroscopy Method for the Determination of Posaconazole in Bulk and Formulation

  2023cites this paper
• Advancing posaconazole quantification analysis with a new reverse-phase HPLC method in its bulk and marketed dosage form

  2023cites this paper
• Posaconazole-amino acid cocrystals for improving solubility and oral bioavailability while maintaining antifungal activity and low In vivo toxicity

  2022cites this paper
• Analytical study of the antifungal posaconazole in raw material: quantitative bioassay, decomposition chemical kinetics and degradation impurities by LC-QTOF-MS.

  2021cites this paper
• UV spectrophotometric method for determination of posaconazole : comparison to HPLC

  2016cites this paper
• Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.

  2015cites this paper
• Hot Melt Extruded Amorphous Solid Dispersion of Posaconazole with Improved Bioavailability: Investigating Drug-Polymer Miscibility with Advanced Characterisation

  2014cites this paper
• Stability-Indicating HPLC Method for Posaconazole Bulk Assay

  2012cites this paper
• Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents-a review.

  2010cites this paper
• Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique.

  2009cites this paper
• HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases

  2006cites this paper
• Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma.

  2003cites this paper
• Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma.

  2002cites this paper
• Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

  2001cites this paper